Literature DB >> 26031776

KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers.

Kyung Ha Lee1, Jin Soo Kim1, Choong Sik Lee2, Ji Yeon Kim1.   

Abstract

BACKGROUND: Although KRAS shows high concordance between primary and metastatic colorectal cancers, recent studies have reported discordance and intra-tumoral heterogeneity. To evaluate KRAS concordance between primary colorectal cancers and recurrent tumors after radical resection, we performed this study.
METHODS: Between January 2007 and August 2013, among patients underwent radical resection for primary colorectal cancers and tissue sampling of recurred tumors including resection or biopsy, 74 patients whose both primary and recurred tumor tissues were available for KRAS analysis were enrolled. The clinical and pathologic data were retrospectively revised and KRAS analyses were performed.
RESULTS: The patients with initial M1 stage showed significantly higher KRAS discordance rate (54.5%). The KRAS concordance rate was 79.7% (n = 59). Forty-two patients (56.8%) showed the wild-to-wild type and 17 (22.9%) showed the mutant-to-mutant type. The discordance rate was 20.3% (n = 15). Eight patients (10.8%) showed the wild-to-mutant type, and 7 (9.5%) showed the mutant-to-wild type. Among 15 discordance cases, intra-tumoral heterogeneity was found in 26.7% (n = 4).
CONCLUSIONS: There is 20.3% KRAS discordance between primary and recurrent tumors, which is higher rate than is generally known. For selection of the effective target agent, KRAS analysis of recurred tumors will be necessary, if it is available.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  KRAS protein; colorectal neoplasms; neoplasm metastasis

Mesh:

Substances:

Year:  2015        PMID: 26031776     DOI: 10.1002/jso.23936

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

2.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

3.  Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer.

Authors:  Jörg Trojan; Susanne Klein-Scory; Christine Koch; Wolff Schmiegel; Alexander Baraniskin
Journal:  Case Rep Oncol Med       Date:  2017-01-23

4.  Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.

Authors:  Daniel R Owen; Hui-Li Wong; Melika Bonakdar; Martin Jones; Christopher S Hughes; Gregg B Morin; Steven J M Jones; Daniel J Renouf; Howard Lim; Janessa Laskin; Marco Marra; Stephen Yip; David F Schaeffer
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

Review 5.  Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy.

Authors:  Irene S Yu; Winson Y Cheung
Journal:  Can J Gastroenterol Hepatol       Date:  2018-11-05

6.  Biomarker concordance between primary colorectal cancer and its metastases.

Authors:  D S Bhullar; J Barriuso; S Mullamitha; M P Saunders; S T O'Dwyer; O Aziz
Journal:  EBioMedicine       Date:  2019-02-04       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.